Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • perampanel

    - PMLiVE

    Eisai submits new drug application for subcutaneous Leqembi in Japan

    LEQEMBI is a treatment for early Alzheimer’s disease

    - PMLiVE

    Biogen and Eisai receive MHRA approval for updated dosing of early Alzheimer’s treatment

    The MHRA approval for IV dosing comes following positive results from the global phase 3 trial

    - PMLiVE

    UCB’s Fintepla shows positives results for Lennox-Gastaut syndrome

    The study demonstrated a sustained reduction in seizures for patients

    - PMLiVE

    Uniphar On Track to Achieve SBTi Target of Halving Scope 1 and 2 Emissions by 2030

    [Dublin, 9th October 2025] Uniphar, a global leader in pharmaceutical and medtech solutions, is making progress towards its near-term Science Based Targets initiative (SBTi) goal of halving Scope 1 and...

    Uniphar

    Epilepsy meds app silver award at PMi Awards

    Genetic Digital Wins Silver at PM Society Digital Awards for Epilepsy Meds Clinical Support App

    Genetic Digital wins Silver at the PM Society Digital Awards for Epilepsy Meds, a clinical support app developed with Desitin and ChangeMed to aid patient-specific prescribing in epilepsy care.

    Genetic Digital

    Streamlining European expansion for cell and gene therapies

    Tom Smith, Strategic Director, Cell and Gene Therapies, Uniphar, discusses the essential elements biotechs need for commercial success in Europe’s unique market when developing cell and gene therapies (CGTs). Europe...

    Uniphar

    - PMLiVE

    Current CGT landscape and future outlook  

    What makes CGT unique  Cell and gene therapy (CGT) is a unique treatment that uses cells and genetic material to treat and cure diseases. Personalized to the patient, CGT’s offer...

    Uniphar

    - PMLiVE

    Building for Success: Aligning Preclinical and Phase 1 Strategy with Commercial Goals 

    This article concludes our three-part series on preparing cell and gene therapies (CGTs) for successful launch and long-term viability. The first article explored the unique scientific and logistical challenges of...

    Uniphar

    - PMLiVE

    Navigating the complexities of launch preparation for Cell and Gene Therapy

    Cell and gene therapies (CGT) provide transformative treatment that can treat conditions that were previously considered untreatable. As described in the previous article in this series, most CGTs target patients...

    Uniphar

    Biogen Idec building

    Biogen/Eisai’s Alzheimer’s drug Leqembi shows continued benefit over four years

    An estimated 13 million people in the US will be living with Alzheimer’s disease by 2050

    Genetic Digital has been shortlisted for a PM Society Digital Award for Epilepsy Meds.

    Genetic Digital Shortlisted for PM Society Digital Award for Epilepsy Meds App

    Genetic Digital has been shortlisted for a PM Society Digital Award for Epilepsy Meds, a mobile-first app that helps healthcare professionals make safer, patient-specific prescribing decisions in epilepsy care. The...

    Genetic Digital

    - PMLiVE

    Uniphar Rebrands On Demand Business to Uniphar Global Sourcing, Strengthening Global Pharmaceutical Offering

    Dublin, Ireland 16th July 2025 – Leading global healthcare services provider, Uniphar, has launched Uniphar | Global Sourcing, a new identity for its On Demand business that strengthens its position...

    Uniphar

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links